Pharmacogenomics of Alzheimer's Disease Treatment

Pharmacogenomics explores how inherited genetic variation influences individual responses to drugs used in Alzheimer’s disease, with the ultimate aim of tailoring therapy to maximise efficacy and minimise adverse effects. In Alzheimer’s treatment, key gene families include drug-metabolising enzymes, notably the cytochrome P450 (CYP) superfamily, transport proteins at the blood–brain barrier, and genes encoding receptors or enzymes targeted by symptomatic treatments such as cholinesterase inhibitors. Common genetic variants, single nucleotide polymorphisms (SNPs) and haplotypes within these genes can alter enzyme activity, drug concentrations in the central nervous system and treatment outcomes. The apolipoprotein E (APOE) genotype further modulates both disease progression and drug response, particularly influencing lipid transport, inflammation and synaptic repair. Epigenetic factors, including DNA methylation, add a dynamic layer that interacts with pharmacogenomic profiles to shape therapeutic benefit. Advances in high-throughput genotyping and bioinformatic analysis have enabled identification of predictive markers for cognitive and behavioural responses, paving the way for personalised dosing strategies, choice of drug class and minimisation of polypharmacy risks. Such precision approaches promise globally significant improvements in care, reduction of health-care costs and enhanced quality of life for patients and caregivers.

Research from Nature Portfolio

A comprehensive meta-analysis of ATP-binding cassette transporter gene variants revealed that specific SNPs in the ABCB1 gene are significantly associated with Alzheimer’s susceptibility. Individuals carrying the 3435T allele and certain combinations of 1236T, 2677T and 3435C in haplotypes showed altered risk profiles, suggesting that transporter-mediated drug efflux at the blood–brain barrier may influence both disease mechanisms and response to pharmacological interventions.

An investigation into nicotinic acetylcholine receptor gene polymorphisms demonstrated that variants in CHRNA7 interact with apolipoprotein E ε4 status and environmental factors such as cigarette smoking. In non-ε4 carriers, particular CHRNA7 alleles conferred reduced Alzheimer’s risk and modulated the detrimental effects of smoking, highlighting the importance of gene–gene and gene–environment interactions in determining therapeutic outcomes.

Pharmacogenomics of Alzheimer's Disease Treatment publication trend

The graph below shows the total number of articles in pharmacogenomics of alzheimer's disease treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Pharmacogenomics: Study of how genetic variation affects individual drug responses.

Single Nucleotide Polymorphism (SNP): A single base-pair change in DNA that can influence gene function or expression.

Cytochrome P450 enzymes: A family of liver enzymes (e.g., CYP2D6, CYP2C19) responsible for the metabolism of many Alzheimer’s drugs.

Apolipoprotein E (APOE): A lipid-transport protein with three major isoforms (ε2, ε3, ε4) that modulates Alzheimer’s risk and treatment response.

Cholinesterase Inhibitors: Drugs that prevent breakdown of acetylcholine, used to alleviate cognitive symptoms in Alzheimer’s disease.

Haplotype: A set of DNA variations, or alleles, inherited together on the same chromosome.

References

1. Influence of Metabolic, Transporter, and Pathogenic Genes on Pharmacogenetics and DNA Methylation in Neurological Disorders. Biology (2023).
2. Association between ABCB1 polymorphisms and haplotypes and Alzheimer’s disease: a meta-analysis. Scientific Reports (2016).
3. CHRNA7 Polymorphisms and Dementia Risk: Interactions with Apolipoprotein ε4 and Cigarette Smoking. Scientific Reports (2016).
4. Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review. Frontiers in Neuroscience (2022).